Pfizer (PFE) Drug Sigvotatug Vedotin Misses Primary Endpoint in Phase 3 NSCLC Study

Pfizer Inc. (PFE) announced on June 23, 2026, that its investigational drug, Sigvotatug Vedotin, failed to meet its primary overall survival (OS) endpoint in a Phase 3 study for non-small cell lung cancer (NSCLC). This outcome represents a significant setback for the company's oncology pipeline. The Phase 3 trial evaluated Sigvotatug Vedotin as a potential treatment for patients with NSCLC. The failure to achieve the primary OS endpoint raises questions about the drug's efficacy and its future development path within Pfizer's portfolio. Further details regarding secondary endpoints or the drug's safety profile were not immediately disclosed. The results are expected to impact Pfizer's strategic considerations for its oncology assets and future revenue projections in the highly competitive cancer treatment market.